|
David Mott became Chief Executive Officer of MedImmune and a member of the AstraZeneca Senior Executive Team upon completion of AstraZeneca’s acquisition of MedImmune, Inc on 18 June 2007.
AstraZeneca’s new biologics business combines MedImmune Inc, Cambridge Antibody Technology and biologics capabilities from across AstraZeneca. The resulting entity is called MedImmune and it will be responsible for the discovery, development, manufacturing and commercialisation of new biologics and vaccines.
Prior to AstraZeneca’s acquisition of the company David Mott was MedImmune Inc’s chief executive officer from October 2000. He joined the company in April 1992 as vice president, with responsibility for business development, strategic planning and investor relations. In 1994, Mr. Mott assumed additional responsibility for the medical and regulatory groups, and in March 1995 was appointed executive vice president and chief financial officer. In November 1995, Mr. Mott was appointed to the position of president and chief operating officer.
Prior to joining the Company, Mr. Mott was a vice president in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc. At Smith Barney, where he was employed from July 1986 to April 1992, Mr. Mott’s activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies.
Mr. Mott is chairman of the board of directors of Conceptis Technologies and also serves on the boards of directors of the Biotechnology Industry Organization (BIO) and the Technology Council of Maryland, the board of trustees of St. James School, and the board of governors of Beauvoir, the National Cathedral Elementary School. He holds a bachelor’s degree in economics and government from Dartmouth College. | 